DWA
ACET icon

Dorsey Wright & Associates’s Adicet Bio ACET Stock Holding History

Dorsey Wright & Associates’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-218
Closed -$70K – 267
2022
Q1 		$70K Buy
+218
New +$50.1K 0.02% 145

Other funds holding ACET

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Dorsey Wright & Associates's ACET Position: Q2 2022 in Review

Dorsey Wright & Associates sold out of Adicet Bio (ACET) in Q2 2022, closing a stake of 218 shares — an estimated $70K sold.

Dorsey Wright & Associates first reported a position in ACET in Q1 2022 and held it in 1 quarter. The position peaked at $70K in Q1 2022. 101 funds tracked by Wall St. Rank hold ACET as of Q2 2022.

  • Dorsey Wright & Associates reported no remaining Adicet Bio position as of Q2 2022 after selling out during the quarter.
  • Dorsey Wright & Associates sold 218 Adicet Bio shares in Q2 2022, an estimated $70K.
  • Dorsey Wright & Associates first reported a position in Adicet Bio in Q1 2022 and held it in 1 quarter.
  • Dorsey Wright & Associates's Adicet Bio position peaked at $70K in Q1 2022.
  • 101 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2022.

Based on Dorsey Wright & Associates's 13F filing for Q2 2022, filed 20 Jul 2022.